Based in Germany, EvlaBio is a startup. Its most recent tracked round is Seed.
EvlaBio develops a selective monoclonal antibody targeting FGFR4 to treat left ventricular hypertrophy in patients with chronic kidney disease by blocking pathological cardiac remodeling caused by aberrant FGF23-FGFR4 signaling.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.